Browse

Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma

DC Field Value Language
dc.contributor.authorKim, Noe Kyeong-
dc.contributor.authorIm, Seock-Ah-
dc.contributor.authorKim, Dong-Wam-
dc.contributor.authorLee, Moon H.-
dc.contributor.authorJung, Chul W.-
dc.contributor.authorCho, Eun K.-
dc.contributor.authorLee, Jong T.-
dc.contributor.authorAhn, Jin S.-
dc.contributor.authorHeo, Dae S.-
dc.contributor.authorBang, Yung-Jue-
dc.date.accessioned2020-04-27T11:47:53Z-
dc.date.available2020-04-27T11:47:53Z-
dc.date.created2020-04-08-
dc.date.created2020-04-08-
dc.date.issued1999-10-
dc.identifier.citationCancer, Vol.86 No.7, pp.1109-1115-
dc.identifier.issn0008-543X-
dc.identifier.other95333-
dc.identifier.urihttps://hdl.handle.net/10371/165584-
dc.description.abstractBACKGROUND. SKI-2053 R (SK Chemicals; Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the efficacy and toxicity of SKI-2053R in the treatment of patients with advanced gastric adenocarcinoma. METHODS. Thirty-seven patients with advanced gastric adenocarcinoma that was unresectable or metastatic were treated. No prior chemotherapy or radiotherapy was allowed. Patients received SKI-2053R 360 mg/m(2) by 1-hour infusion on Day. After the first cycle, subsequent doses were adjusted according to the toxicity. Courses were repeated every 28 days. RESULTS. Thirty-five patients were evaluable for response and toxicity. Six patients achieved a major response (17%; 95% confidence interval, 8-33%); 2 were complete and 4 were partial responses. The median duration of response was 7.2 months, with a range of 1-20 months. Patients could tolerate the treatment without significant toxicity. No patients had Grade 3 or 4 toxicity. The most frequent toxicity was Grade 1 or 2 proteinuria (26% of cycles), but it was mild and transient. Leukopenia, thrombocytopenia, azotemia, nausea and vomiting, and neurotoxicity were not frequent. These low toxicity profiles indicated that the dose of SKI-2053R could be increased in future studies. CONCLUSIONS. SKI-2053R was active in the treatment of patients with gastric adenocarcinoma and had favorable toxicity profiles. Cancel 1999;86:1109-15. (C) 1999 American Cancer Society.-
dc.language영어-
dc.publisherJohn Wiley & Sons Inc.-
dc.titlePhase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma-
dc.typeArticle-
dc.contributor.AlternativeAuthor임석아-
dc.identifier.doi10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO;2-G-
dc.citation.journaltitleCancer-
dc.identifier.wosid000082749200003-
dc.identifier.scopusid2-s2.0-0033214158-
dc.citation.endpage1115-
dc.citation.number7-
dc.citation.startpage1109-
dc.citation.volume86-
dc.identifier.sci000082749200003-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Noe Kyeong-
dc.contributor.affiliatedAuthorIm, Seock-Ah-
dc.contributor.affiliatedAuthorKim, Dong-Wam-
dc.contributor.affiliatedAuthorHeo, Dae S.-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
dc.type.docTypeArticle; Proceedings Paper-
dc.description.journalClass1-
dc.subject.keywordPlusANTITUMOR-ACTIVITY-
dc.subject.keywordPlusCOMBINATION CHEMOTHERAPY-
dc.subject.keywordPlusCISPLATIN-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusDOXORUBICIN-
dc.subject.keywordPlus5-FLUOROURACIL-
dc.subject.keywordPlusCARBOPLATIN-
dc.subject.keywordPlusMITOMYCIN-
dc.subject.keywordPlusPHARMACOKINETICS-
dc.subject.keywordPlusRESISTANCE-
dc.subject.keywordAuthorSKI-2053R-
dc.subject.keywordAuthorgastric carcinoma-
dc.subject.keywordAuthorchemotherapy-
dc.subject.keywordAuthorclinical trial-
dc.subject.keywordAuthorPhase II study-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Journal Papers (저널논문_의학과)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse